Johnson & Johnson (JNJ) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal first quarter ended March 30, 2025. Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The quarter was significantly impacted by a major legal accounting adjustment regarding talc litigation reserves and the closing of the Intra-Cellular Therapies acquisition immediately following the period end.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Net Sales | $21.89 billion | $21.38 billion | +2.4% |
| Gross Profit | $14.54 billion | $14.87 billion | -2.2% |
| Net Earnings | $11.00 billion | $3.26 billion | +236% |
| Diluted EPS | $4.54 | $1.34 | +239% |
| Operating Cash Flow | $4.17 billion | $3.66 billion | +14% |
| Cash & Equivalents | $38.47 billion | $24.11 billion | +59.6% |
| Total Debt | $52.25 billion | $33.60 billion | +55.5% |
Note: Net earnings and EPS are non-representative of core operating performance due to a $7.0 billion reversal of talc litigation reserves.
Material Changes vs. Prior Period
- Talc Litigation Reversal: The most significant driver of financial results was the reversal of approximately $7.0 billion in previously accrued talc reserves following the dismissal of the "Red River" bankruptcy case by the Texas Bankruptcy Court on March 31, 2025. This resulted in a massive reduction in "Other (income) expense, net."
- Debt Issuance: Total debt increased by nearly $19 billion, driven by the issuance of approximately $9.2 billion in senior unsecured notes in Q1 2025 to fund the pending Intra-Cellular Therapies acquisition and general corporate purposes.
- Segment Performance:
- Innovative Medicine: Sales grew 2.3% (operational growth of 4.2%). Growth was led by Oncology (+17.9%) and Cardiovascular (+22.3%), offset by a 33.7% decline in Immunology sales due to biosimilar competition for STELARA.
- MedTech: Sales grew 2.5% (operational growth of 4.1%), driven by the Shockwave Medical acquisition (contributing $258 million) and Cardiovascular growth (+16.4%). Orthopaedics declined 4.2% due to restructuring impacts and one-time events.
- Acquisitions: The company completed the acquisition of Intra-Cellular Therapies on April 2, 2025, for approximately $14.6 billion. Results will be included in the Innovative Medicine segment starting from the acquisition date.
Outlook, Risks, and Contingencies
- Talc Litigation Status: With the bankruptcy dismissal, the automatic stay on talc litigation was dissolved. The company expects to continue litigating claims in the tort system. The remaining talc reserve is approximately $4.2 billion (present value), covering mesothelioma and other claims.
- Opioid Litigation: Approximately 70% of the $5.0 billion state/subdivision settlement has been paid. The company anticipates settling remaining hospital cases and defending remaining government and private litigants. Remaining exposure is estimated at approximately $1.5 billion.
- Patent Expirations & Biosimilars: Continued revenue pressure is expected from STELARA biosimilar launches in the U.S. and Europe. The company is actively defending patents for key products including XARELTO, INVEGA SUSTENNA, and SPRAVATO.
- Regulatory & Tax: The company faces ongoing scrutiny regarding the Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program. The effective tax rate increased to 19.3% in Q1 2025 from 12.4% in Q1 2024, primarily due to higher income in U.S. jurisdictions.
Investor Verification Checklist
- Non-GAAP Adjustments: Verify the exclusion of the $7.0 billion talc reserve reversal when analyzing core profitability and future earnings guidance.
- Debt Servicing: Confirm the impact of the increased debt load ($52.3 billion) on interest expense and liquidity, particularly given the recent $9.2 billion note issuance.
- Talc Reserve Adequacy: Monitor the $4.2 billion remaining talc reserve against the volume of reactivated lawsuits following the bankruptcy dismissal.
- STELARA Decline: Assess the trajectory of STELARA sales decline as biosimilar competition intensifies in 2025.
- Intra-Cellular Integration: Track the integration progress and financial contribution of the Intra-Cellular Therapies acquisition in subsequent quarters.